Darren Schmidt, MD
Nephrology · Albuquerque, NMNPI 1134159692
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $980 of the $1,565 with a category attached, or 62.6%. Bayer accounts for 78.3% of it on its own, with 6 other manufacturers making up the rest. 2023 is the largest year on record at $1,318, more than ten times the $80 reported in 2019.
Across 24 payments — averaging $65.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$1K
- Otsuka America Pharmaceutical, Inc.$169
- Amgen$72
- Viiv Healthcare Company$58
- Sanofi Pasteur Inc.$19
- AstraZeneca$18
- plus $3 from 1 others
Across 20 payments — averaging $4144.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$83K
What the payments were for
- Travel & lodging$98063%
- Food & beverage$44829%
- Education$1379%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 11 | $1,225 |
| Otsuka America Pharmaceutical, Inc. | 6 | $169 |
| Amgen | 1 | $72 |
| Viiv Healthcare Company | 3 | $58 |
| Sanofi Pasteur Inc. | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Travere Therapeutics, Inc. | 1 | $3 |
How this compares
$1,565 in reported general payments places this provider in the 55th percentile of 68 nephrology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 31 | $39,848 |
| Sevelamer Carbonate | 62 | $25,769 |
| FarxigaDapagliflozin Propanediol | 15 | $12,724 |
| Calcium Acetate | 30 | $1,572 |
| Bumetanide | 17 | $1,248 |
| Irbesartan | 24 | $1,071 |
| Amiloride Hcl | 19 | $652 |
| Nifedipine ErNifedipine | 23 | $651 |
| Telmisartan | 18 | $627 |
| Furosemide | 78 | $561 |
| Potassium Chloride | 21 | $545 |
| Losartan Potassium | 57 | $542 |
| Tamsulosin Hcl | 27 | $472 |
| Chlorthalidone | 29 | $405 |
| Torsemide | 12 | $383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $18 | $12,72415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 68 nephrology providers in New Mexico.
Other nephrology in Albuquerque
- Satyaki BanerjeeAlbuquerque$260K
- Christos ArgyropoulosAlbuquerque$32K
- Arun RajasekaranAlbuquerque$32K
- George Vasquez RiosAlbuquerque$25K
- Jayant KumarAlbuquerque$12K
- Luis Madera MarinAlbuquerque$7K
- Hector CastroAlbuquerque$7K
- Chudi AdiAlbuquerque$7K
- Dale EricksonAlbuquerque$6K
- Lei ChenAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.